CARMEL, Ind., Oct. 22, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing ...
NeurAxis, Inc. has announced new medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, specifically the IB-Stim device, by two health insurers in ...
Total national coverage footprint for PENFS increases to over 147 million covered livesCARMEL, Ind., Oct. 15, 2026 (GLOBE NEWSWIRE) -- (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical ...
Urine Cytology Adds Little to Hematuria Investigation In most responders, overactive bladder symptom improvement sustained to three years. Percutaneous tibial nerve stimulation with the Urgent PC ...
The procedure is ideal in this population because it is minimally invasive and highly efficacious. Overactive bladder (OAB) is estimated to affect more than 33 million adults in the United States ...
A network meta-analysis of 115 randomized controlled trials finds that low-frequency spinal cord stimulation carries the strongest evidence for treating neuropathic pain, while non-invasive brain ...
Stimvia s.r.o. recently secured Medical Device Regulation certification for its Uris neuromodulation system to deliver both percutaneous tibial nerve stimulation and peroneal electrical transcutaneous ...
Cala Health, a wearable neuromodulation therapy startup with Stanford University roots, has signed a licensing deal with Partners Healthcare affiliate Massachusetts General Hospital that will provide ...
ReShape Lifesciences® announced the granting of an international patent for its Diabetes Neuromodulation technology from the Australian Patent Office, providing protection until April 12, 2039. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results